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ABSTRACT
Bone fractures occur in horses following traumatic and non-traumatic
(bone overloading) events. They can be difficult to treat due to the
need for the horse to bear weight on all legs during the healing period.
Regenerative medicine to improve fracture union and recovery could
significantly improve horse welfare. Equine induced pluripotent stem
cells (iPSCs) have previously been derived. Here we show that
equine iPSCs cultured for 21 days in osteogenic induction media on
an OsteoAssay surface upregulate the expression of osteoblast
associated genes and proteins, including COL1A1, SPARC, SPP1,
IBSP, RUNX2 and BGALP. We also demonstrate that iPSC-
osteoblasts are able to produce a mineralised matrix with both
calcium and hydroxyapatite deposition. Alkaline phosphatase activity
is also significantly increased during osteoblast differentiation.
Although the genetic background of the iPSC donor animal
affects the level of differentiation observed after 21 days of
differentiation, less variation between lines of iPSCs derived
from the same horse was observed. The successful, direct,
differentiation of equine iPSCs into osteoblasts may provide a
source of cells for future regenerative medicine strategies to
improve fracture repair in horses undergoing surgery. iPSC-
derived osteoblasts will also provide a potential tool to study
equine bone development and disease.
KEY WORDS: Equine, Induced pluripotent stem cells, Osteoblast,
Differentiation, Gene expression
INTRODUCTION
Fractures occur in horses from a direct trauma, such as a kick, as
well as from bone overloading. They occur in all types of horses
(Morgan and Dyson, 2012), with horses that take part in strenuous
activities such as racing being at particularly high risk of having a
fracture resulting from overloading (Verheyen and Wood, 2004).
Numerous environmental risk factors have been identified that
contribute to fracture risk (Anthenill et al., 2007; Kristoffersen et al.,
2010; Parkin et al., 2004; Verheyen et al., 2006). More recently,
fracture in racing Thoroughbred horses has also been shown to have
a genetic basis (Blott et al., 2014; Welsh et al., 2014). Similarly,
genetic (Bulathsinhala et al., 2017; Korvala et al., 2010; Zhao et al.,
2016) and environmental (Warden et al., 2006, 2007) factors have
also been implicated in stress fractures in human athletes and
military personnel.
While severe fracture in horses usually leads to euthanasia, smaller
fractures can be treated conservatively with box rest and a cast. In
delayed union or comminuted fractures, surgery is required (Cahn,
2010), but up to 40% of horses do not return to their previous athletic
activity (Payne and Compston, 2012). Regenerative medicine to
improve fracture reunion and recovery could therefore significantly
improve horse welfare (Govoni, 2015). Bone grafts are used to
promote bone regeneration and restore normal bone architecture in
humans, however, it is difficult to obtain sufficient tissue without
donor site morbidity. Using stem cells to enhance tissue healing is
therefore becoming a popular alternative (Ma et al., 2014).
Equine mesenchymal stem cells (MSCs) are widely reported to
differentiate into bone (De Schauwer et al., 2011; Glynn et al., 2013;
Guest et al., 2008; Nino-Fong et al., 2013). However, like human
MSCs, equine MSCs are heterogeneous and show donor variability
in many of their properties including osteoblast differentiation
(Carter-Arnold et al., 2014). Methods have been established to
differentiate human induced pluripotent stem cells (iPSCs) into
osteoblasts with the aim of using these cells in bone tissue
engineering strategies and modelling human bone disorders,
reviewed in (Csobonyeiova et al., 2017).
Equine induced pluripotent stem cells (iPSCs) have been derived
by ourselves (Bavin et al., 2015) and others (Breton et al., 2013;
Khodadadi et al., 2012; Lee et al., 2016; Nagy et al., 2011;
Quattrocelli et al., 2016; Sharma et al., 2014; Whitworth et al.,
2014). Their ability to undergo differentiation into the three germ
layers and capacity for unlimited self-renewal in vitro, underpins
their potential applications in regenerative medicine. Establishing
methods to differentiate iPSCs into bone forming osteoblasts would
therefore open up the possibility of using these cells clinically to
improve fracture repair after surgery or in in vitro disease modelling
of bone disorders. However, due to the pluripotent nature of iPSCs,
robust methods for differentiation need to be established to ensure
that no undifferentiated iPSCs with the potential to form tumours
remain (Liu et al., 2013).
Horses can provide a useful large animal model for human
musculoskeletal injuries (Innes and Clegg, 2010). Unlike small
laboratory species, horses naturally suffer from musculoskeletal
conditions and therefore, horse repair models may more closely
resemble the human situation. Added to this, the equine
musculoskeletal system is of a more similar size and load bearing
stress to that of humans. This allows the assessment of treatments for
injuries with similar dimensions to those observed in human
patients in the clinic. The horse therefore provides a relevant species
with which to investigate the genetic mechanisms involved in
fracture risk and to test novel regenerative therapies.
Here, we demonstrate for the first time that equine iPSCs can
differentiate directly into functional osteoblasts in vitro.Received 13 February 2018; Accepted 11 April 2018
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RESULTS
Equine iPSCs derivation
Five lines of iPSCs were derived from three donor horses (one line
from each of two horses, three lines from one horse). Two of the
iPSC lines used in this study have previously been characterised
for their normal karyotype, expression of pluripotency markers,
and ability to differentiate into derivatives of endoderm, ectoderm
and mesoderm (Bavin et al., 2015). The remaining lines underwent
the same characterisation. All lines expressed pluripotency markers
and underwent spontaneous differentiation into endoderm,
ectoderm and mesoderm when cultured in the absence of feeder
cells, leukaemia inhibitory factor, and basic fibroblast growth
factor (Fig. S1).
Equine iPSCs differentiate into cells with the molecular
signature of osteoblasts
When cultured in osteogenic media on a surface designed to
promote osteogenic differentiation [OsteoAssay (OA)], iPSCs
differentiated into cells that expressed COL1A1 (collagen type I),
SPARC (osteonectin), SPP1 (osteopontin), IBSP (bone
sialoprotein), RUNX2 (Runt related transcription factor 2) and
BGALP (osteocalcin) (Fig. 1).
Equine iPSCs produce osteoblast-associated proteins
following differentiation
Undifferentiated iPSCs do not express any detectable osteoblast-
associated proteins, whereas following 21 days in osteoblast
induction media, COL1A1, SPARC, SPP1, IBSP, RUNX2 and
BGALP are all detected in the differentiated cells (Fig. 1).
Equine iPSC osteoblasts are functional and can produce a
calcified mineralised matrix
In the presence of osteogenic induction media, iPSCs stained
positively for hydroxyapatite and calcium deposition after 21 days
of culture. In contrast, there was very little, or no detection of
hydroxyapatite and calcium deposition after 21 days when the cells
were cultured in non-osteogenic induction media (Fig. 2).
Hydroxyapatite was detected with a commercial bone
mineralisation assay. Calcium deposition was detected using both
Alizarin Red S staining and von Kossa staining. The osteoassay
Fig. 1. Osteoblast-associated gene and protein expression in equine iPSCs differentiated in osteogenic media on an OsteoAssay surface for
21 days. (A) Quantitative PCR analysis of osteoblast-associated genes. The mean of three independent replicates is shown. Error bars represent the s.e.m.
and the relative expression (to the 18S housekeeping gene) is plotted on a log10 scale. (B) Immunocytochemistry is shown to detect osteoblast-associated
proteins in undifferentiated iPSCs and iPSCs after 21 days of differentiation in osteogenic media. All proteins are detected following differentiation [(Ai–Eii)
red staining; (Fi,Fii) green staining]. Negative controls for the secondary antibodies were performed on differentiated iPSCs (G) donkey anti-goat alexafluor
594. (H) Goat anti-rabbit alexafluor 594. (I) Goat anti-mouse FITC. DAPI staining of cell nuclei is shown in blue. Scale bars: 40 μm. Immunocytochemistry
was performed on all lines of iPSCs and representative images are shown.
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surface used for bone differentiation resulted in positive staining
with Alizarin Red S in the absence of any bone cells due to its
calcium phosphate coating. Therefore, Alizarin Red S staining was
performed on iPSCs which had been differentiated for 21 days on
normal tissue culture plastic.
Equine iPSC osteoblasts synthesise alkaline phosphatase
Alkaline phosphatase activity was detected in the undifferentiated
equine iPSCs but was significantly increased by approximately
sixfold over the 21 days of differentiation in OA-induction media
(Fig. 2).
The genetic background of the iPSCs affects their efficiency
of differentiation into osteoblasts but there is little variation
within lines derived from the same individual
The relative level of expression of osteoblast genes varied between
the three lines of iPSCs that were derived from three different
horses. Some lines displayed a greater level of expression of
osteoblast genes than others.
In contrast, three different iPSC lines isolated from the same
horse were more similar in their levels of expression of osteoblast
genes and, generally, had lower levels of variation than iPSC lines
established from different horses (Fig. 3).
There are no significant differences in the mean expression value
from between horses versus within one horse for any of the genes.
DISCUSSION
Here, we demonstrate for the first time that equine iPSCs can
differentiate directly into functional osteoblasts when cultured on an
OsteoAssay surface for 21 days in osteogenic media. Equine iPSCs
have been shown to differentiate into MSC-like cells that can
produce mineralisation (Lepage et al., 2016), however, detailed
analysis of the cells was not reported and direct differentiation from
the iPSCs was not tested.
Fig. 2. iPSCs produce functional osteoblasts. (A) A mineralised matrix is deposited by iPSCs cultured in osteoinduction media for 21 days but not by cells
cultured in non-osteoinductive media for the same time period. Positive hydroxyapatite staining detected under fluorescent light is shown in green. Positive
staining for calcium deposition is shown in red for Alizarin Red S and black for von Kossa. Scale bars: 100 μm. Representative images from across all lines of
iPSCs are shown. (B) Alkaline phosphatase activity is significantly upregulated following 21 days of differentiation of iPSCs on an OsteoAssay surface in
osteogenic media. An unpaired Student’s t-test was used to demonstrate statistically significant differences in the mean ALP values (*P<0.05).
Fig. 3. The donor affects osteoblast gene expression by differentiated iPSCs. Box and whisker plots to demonstrate the variation in relative osteogenic-
associated gene expression as measured using quantitative PCR on three lines of iPSCs derived from different individuals (grey bars) and three lines of
iPSCs derived from the same individual (blue bars). An unpaired Student’s t-test was used to demonstrate that there are no significant differences in the
mean expression value from between horses versus within one horse for any of the genes.
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The iPSCs lines used in these experiments had either been
characterised previously (Bavin et al., 2015) or they were
characterised in this work for their expression of pluripotency
markers and ability to undergo tri-lineage differentiation in the
absence of feeder cells, LIF and bFGF (Fig. S1).
The media used in our experiments included β-glycerophosphate,
ascorbic acid and dexamethasone. These factors have all been
shown to be involved in driving the differentiation of stem cells into
osteoblasts. β-glycerophosphate provides a source of phosphate for
the formation of hydroxyapatite (HA), dexamethasone induces and
enhances Runx2 activity, and ascorbic acid promotes the secretion
of collagen type I (Langenbach and Handschel, 2013). We
demonstrated that these factors are required for the production and
deposition of calcium and hydroxyapatite by iPSCs, as 21 days of
culture in non-osteogenic media did not result in detectable calcium
and hydroxyapatite deposition.
A combination of both Alizarin Red S and von Kossa staining
were used to detect calcium deposition. Although von Kossa is
widely used to determine calcium deposition during osteoblast
differentiation, it can react with the anionic portion of phosphates,
carbonates, and other salts, and is therefore not specific for calcium
(Bonewald et al., 2003). Alizarin Red S staining binds directly to
calcium, meaning it can cross react with calcium on the surface of
OsteoAssay plates. As such, Alizarin Red S staining was performed
on iPSCs that were differentiated for 21 days on a normal tissue
culture surface. Immunocytochemistry was performed on cells
cultured on gelatin-coated coverslips rather than on OsteoAssay
plates. Positive staining was observed suggesting that an
OsteoAssay surface is not essential for iPSCs to differentiate into
functional osteoblasts. Furthermore, we were able to detect HA
deposition at similar levels on normal tissue culture and OsteoAssay
plates (data not shown). Calcium phosphate coatings have
previously been shown to induce the osteogenic differentiation of
human iPSCs in the absence of osteogenic factors (Kang et al.,
2014). In our study, we found that the culture of equine iPSCs for
21 days on the OsteoAssay plates in media lacking osteogenic
factors did not result in the production of a mineralised matrix
(Fig. 2). Therefore, the use of OsteoAssay plates alone was not
sufficient to induce functional osteogenic differentiation of equine
iPSCs in this study.
Alkaline phosphatase (ALP) is required for bone mineralisation
(Golub and Boesze-Battaglia, 2007). There are four isoenzymes of
ALP encoded by four genes. Three of the isoenzymes encode tissue
specific ALP (intestinal, placental and germ cell), whereas the
fourth isoenzyme is tissue non-specific ALP (TNAP), and different
isoforms of TNAP are expressed in bone, liver and kidneys. Human
and mouse ESCs and iPSCs have been reported to express TNAP
(Štefková et al., 2015). Therefore, it is not surprising that we
detected some ALP activity in media taken from undifferentiated
equine iPSCs. However, ALP activity was significantly increased
after 21 days of osteoblast differentiation. Taken together, the ALP
activity and other results presented in this study support the
successful differentiation of equine iPSCs into functional
osteoblasts.
The expression of six genes associated with osteoblast
differentiation was also determined. After 21 days of
differentiation in osteoinduction media, iPSCs expressed
COL1A1, SPARC, SPP1, RUNX2, IBSP and BGALP. RUNX2 is a
key transcription factor that drives the expression of multiple bone
genes including COL1A1, SPP1, and IBSP (Komori, 2010).
COL1A1 (collagen type I) is one of the main constituents of bone
and is required for bone strength (Viguet-Carrin et al., 2006).
SPARC (osteonectin) is the most abundant non-collagenous protein
in bone (Termine et al., 1981). SPP1 (osteopontin) is involved in the
regulation of bone remodelling and bone differentiation (Huang
et al., 2004). IBSP (Integrin Binding Sialoprotein) is required for
bone mineralisation and osteoblast differentiation (Bouleftour et al.,
2016). BGALP (osteocalcin) is produced by mature osteoblasts and
is involved in the regulation of bone mineralisation (Zoch et al.,
2016). The expression of these genes by iPSCs that were cultured
for 21 days in osteoinduction media supports the conclusion that
these iPSCs have differentiated into osteoblasts.
We next confirmed that we could also detect proteins for all of the
above osteoblast-associated markers by immunocytochemistry. We
have previously demonstrated by Western blotting that the antibody
to COL1A1 can cross react specifically with the equine protein
(Barsby and Guest, 2013). Antibodies to SPP1 (Miragliotta et al.,
2016) and SPARC (Miragliotta et al., 2009) have similarly been
demonstrated to cross react specifically with their respective equine
proteins. The antibodies to RUNX2 and BGALP have previously
been used to detect bone differentiation in equine cells (McCarthy
et al., 2012). The expression of these proteins is further proof that
our iPSCs have differentiated into functional osteoblasts. Western
blots of the proteins were not carried out in this study due to the
technical difficulty in efficiently extracting a representative sample
of protein from the mineralised matrix that had been formed by the
iPSCs following their differentiation (Cleland et al., 2012).
Due to the production of a mineralised matrix it was also not
possible to isolate the osteoblast-differentiated cells for flow
cytometry to quantify the percentage of cells that were
differentiating. Further work must therefore be performed to
determine if the variability observed in the gene expression is due
to lower levels of expression by osteoblast-differentiated cells, or
whether it is due to a lower percentage of cells differentiating to the
same degree in some lines.
Sex and genetic factors have previously been shown to influence
osteoblast differentiation of mouse mesenchymal stem cells using
cells derived from different strains of inbred mice (Zanotti et al.,
2014). In this study, we used iPSCs derived only from male horses
to avoid any variability due to sex. We demonstrated that the genetic
background of the horse affects the level of osteoblast-associated
gene expression after 21 days of differentiation, and large variations
in the expression of osteoblast genes was observed between iPSCs
from different horses. Although the donor cell type has been shown
to have less effect than genetic background on the differentiation of
human iPSCs (Heslop et al., 2017), donor cell type has been shown
to influence the differentiation potential of equine iPSCs to other
cell lineages (Quattrocelli et al., 2016). Therefore, in this study all
iPSCs were derived from adult horse fibroblasts at early passage
(less than P5) to ensure that any epigenetic memory of tissue source
was the same between all lines (Liang and Zhang, 2013). The high
levels of variation between lines derived from different animals was
expected as each horse is an independent system, and the levels of
expression of these genes is likely to be influenced by factors such
as unique genetic polymorphisms that are maintained when iPSCs
are established from each horse. The genetic background of human
iPSCs has been shown to have the greatest influence on
differentiation to hepatocytes (Heslop et al., 2017). However, to
our knowledge this is the first time that the effect of donor variation
on osteoblast differentiation from iPSCs has been examined in any
species. When three clonal lines of iPSCs derived from the same
horse were compared for their osteoblast-associated gene
expression, we found smaller variations in the levels of expression
of these genes, which is consistent with what we would expect. The
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inter- and intra-individual variation of RUNX2 level was very
similar, with a very similar mean value produced within and
between horses. Therefore RUNX2 was expressed at a comparable
level between horses, which may reflect its importance as the master
regulator of bone differentiation. The variation between lines of
iPSCs derived from the same horse can be due to technical variation
in the experimental set up as well as variation induced by the
reprogramming process. The iPSCs used in this study were
generated using integrating retroviral vectors which integrate at
random sites in the genome (Varas et al., 2009). This may result in
heterogeneity between clonal lines of iPSCs derived from the same
individual, and the integration sites of the virus have the potential to
affect the differentiation capacity of these cells (Zheng et al., 2013).
All of the lines of iPSCs used in this study were generated
independently to ensure that the lines derived from the same horse
would have the same levels of technical variation as the lines
derived from different horses. However, our results show that,
irrespective of the effects that may result from sites of viral
integration or any other technical variability, our iPSCs all have the
capacity to differentiate into functional osteoblasts on exposure to
osteoinduction media for 21 days.
Prior to their clinical application, it is necessary to derive equine
iPSCs using non-integrating methods, however, to date there
are no reports of this having been done in horses. Additionally,
differentiation of human iPSCs into osteoblasts using 3-dimensional
scaffolds has been performed (Csobonyeiova et al., 2017) and this is
likely to represent the next stage of the work to move equine iPSC
towards clinical applications to aid bone regeneration.
CONCLUSIONS
In this study, we have demonstrated that equine iPSCs can be
differentiated directly into functional osteoblasts. We have also
shown that the genetic background of the donor affects the levels of
expression of osteoblast-associated genes. This work demonstrates
the future potential of using equine iPSCs as a source of cells to aid
fracture repair in horses, and as a tool to study bone development
and disease.
MATERIALS AND METHODS
iPSC derivation and culture
iPSCs were generated from male equine skin fibroblasts by retroviral
transduction using methods reported previously (Bavin et al., 2015).
Fibroblasts were isolated from skin biopsies of three adult male horses
[taken post-mortem with the approval of the Animal Health Trust ethical
review committee (AHT_02_2012)] by digesting in cell culture media
[Dulbecco’s modified Eagle medium (DMEM) high glucose, supplemented
with 10% fetal calf serum, 1% penicillin–streptomycin, 2 mM L-glutamine
and 1% fungizone (all from Invitrogen)] with 1 mg/ml collagenase type I
added from Clostridium histolyticum (Sigma-Aldrich) and incubated at
37°C overnight. Fibroblasts were cultured in this media but without
fungizone at 37°C, 5% CO2 until confluent. Fibroblast cells were passaged
at confluency with trypsin-EDTA (Sigma-Aldrich) for expansion and stocks
were frozen in media with 10% DMSO. iPSC generation was performed as
described in Baird et al. (2015) and Bavin et al. (2015). Briefly, phoenix
gag-pol packaging cells were transfected with 3 µg of pVPack-VSV-G
(Agilent technologies, Stockport, UK) along with 3 µg of pMXs.hOct4
(Addgene 17217), pMXs.hSox2 (Addgene 17218), pMXs.hKlf4 (Addgene
17219), pMXs.hc-Myc (Addgene 17220), or pMX.GFP (Cell Biolabs, San
Diego, USA). Transfections were carried out using lipofectamine 2000 and
Opti-MEM media (both Invitrogen) according to the manufacturer’s
instructions. After 48 h culture supernatant containing the viral particles
was pooled, filtered through a 0.45 µM filter (Nalgene), supplemented with
1 µg/ml polybrene (Sigma-Aldrich) and used to infect equine skin
fibroblasts which had been plated at a density of 1×104 the day before
infection.
Three rounds of viral infection were carried out at 48 h intervals prior to
plating the infected cells at a density of 5×103 cells per 10 cm plate pre-seeded
with feeder cells (mitotically inactivated mouse embryonic fibroblasts). The
media was replaced with iPSCmedia [DMEM/F12, supplemented with: 15%
FCS, 2 mM L-glutamine, 1% non-essential amino acids, 1 mM sodium
pyruvate, 0.1 mM 2-mercaptoethanol (all Invitrogen), 1000 U/ml leukaemia
inhibitory factor (LIF, Sigma-Aldrich), and 10 ng/ml basic fibroblast growth
factor (bFGF, Peprotech, London, UK)]. iPSCmediawas replaced every other
day until iPSC colonies began to appear and reached a large enough size to
manually pick selected colonies. These colonies were used to establish clonal
iPSC lines. iPSCs were mechanically passaged in the presence of 2 μM
Thiazovivin (StemGent, Cambridge, USA) and frozen in iPSC media
containing 10% DMSO. iPSCs were used at passage 9–15 for all osteoblast
differentiation studies. For spontaneous differentiation to confirm
pluripotency, the iPSCs were cultured in iPSC media without LIF, bFGF or
feeders for 7 days prior to use in immunocytochemistry. For embryoid body
formation the iPSCs were plated in this media on low attachment plates
(Corning Life Sciences, Tewksbury, USA) for 14 days.
Osteoblast differentiation
To induce osteoblast differentiation, iPSCs were plated (in colony pieces) at
a density of 7×104 cells per well of a 24-well OsteoAssay surface coated
plate (Corning, Wiesbaden, Germany) in iPSC media. The following day,
the media was replaced with osteogenic media [DMEM/F12, supplemented
with: 15% FCS, 2 mM L-glutamine, 1% non-essential amino acids, 1 mM
sodium pyruvate, 0.1 mM 2-mercaptoethanol (all Invitrogen), 10 mM β-
glycerophosphate, 10 nM dexamethasone and 28 µM ascorbic acid (all
Sigma-Aldrich)]. Cells were cultured for 21 days with the media replaced
every 2–3 days prior to analysis.
To determine matrix mineralisation, von Kossa staining (Abcam,
Cambridge, UK) was carried out according to the manufacturer’s
instructions. Alizarin Red S staining for calcium deposition was also
performed by incubating differentiated iPSCs with 2% Alizarin Red S
pH 4.2 for 5 min. Hydroxyapatite deposition was detected using the
OsteoImage bone mineralisation assay (Lonza, Slough, UK) according
to the manufacturer’s instructions. Alkaline phosphatase activity was
measured using a quantitative colorimetric test on cell culture supernatant
(Abcam) according to the manufacturer’s instructions.
RNA extraction, CDNA synthesis and quantitative PCR
RNA was extracted using Tri-reagent (Sigma-Aldrich), purified using the
RNeasy mini kit (Qiagen) and treated with Ambion DNA-free (Life
Technologies). cDNA was made from 1 μg of RNA using the sensiFAST
Table 1. Primer sequences for equine gene transcripts
Gene Forward Reverse
18S CCCAGTGAGAATGCCCTCTA TGGCTGAGCAAGGTGTTATG
COL1A1 TGCGAAGACACCAAGAACTG GACTCCTGTGGTTTGGTCGT
SPARC TGGCGAGTTTGAGAAGGTGT TTTGCAAGGCCCGATGTAGT
SPP1 AGCCCCAGGAAAAATCGCTG GGCATAAGCAAATCACGGCA
IBSP GGACTGCACACGGAAACAATC ACAGGCCATTCCCAAAATGC
RUNX2 CCAAGTGGCAAGGTTCAACG AACTCTTGCCTCGTCCACTC
BGALP GTCTCGGGGTTCCAAGGTTA AATCTCTGGTAGCTGTGTTGGT
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cDNA synthesis kit (Bioline, London, UK). 2 μl aliquots of cDNA were
used in qPCR. Primers were designed using NCBI Primer-Blast (https://
www.ncbi.nlm.nih.gov/tools/primer-blast/). Primer sequences can be found
in Table 1. Quantitative PCR (qPCR) was carried out using SYBR Green
containing supermix (Bioline) on the Bio-Rad C1000 Touch Thermal
Cycler (Bio-Rad), and all PCR reactions performed in duplicate. PCR cycle
parameters were 95°C for 10 min, followed by 40 cycles of 95°C for 15 s, 60°C
for 15 s and 72°C for 15 s. At the end of the program amelt curvewas produced
by taking readings every 1°C from 65°C to 95°C. The levels of 18S rRNA did
not change between treatments (data not shown) and it was used to normalise
gene expression using the 2−ΔΔCt method (Livak and Schmittgen, 2001). An
unpaired Student’s t-test was used to determine significant differences in the
mean gene expression using iPSCs from three independent horses versus three
lines of iPSCs derived from the same horse.
Immunocytochemistry
Cells were cultured on gelatin-coated (Sigma-Aldrich) coverslips, fixed in 3%
paraformaldehyde for 20 min and permeabilised for 1 h with 0.1% triton-X-
100. They were washed in PBS and incubated with the primary antibodies
overnight at 4°C before detection with an appropriate fluorescently labelled
secondary antibody. All antibodies were used at optimized concentrations in
PBS and appropriate negative controls were performed using secondary
antibodies alone and IgG matched to the host species, as well as specific
isotype of the primary antibody. Coverslips were mounted using Vectashield
Hardset mounting medium containing DAPI (4′,6-diamidino-2-
phenylindole, Vector Laboratories, Cambridge, UK). Primary antibodies
included: rabbit anti-alpha fetoprotein 1:500 (Biorbyt, orb7822,
Cambridge, UK), mouse anti-actin 1:200 (Dako, M0635, Cambridge,
UK), mouse anti-Beta-III tubulin 1:100 (Sigma-Aldrich, T8660), mouse
anti-SSEA-4 1:100 (MAB4304, Millipore), mouse anti-SSEA-1 1:100
(Chemicon, MAB4301), rat anti-SSEA-3 1:100 (Chemicon, MAB4303),
mouse anti-TRA-1-60 1:500 and mouse anti-TRA-1-81 1:500 (both
kindly provided by Prof Peter Andrews at the University of Sheffield,
UK), rabbit anti-Oct 4 1:100 (Abcam, Ab18976), mouse anti-collagen
type I 1:100 (Abcam, Ab90395), mouse anti-osteonectin (SPARC) 1:20
(Bio-Techne, mab941-100, Oxford, UK), mouse anti-osteopontin (SPP1)
1:50 (Santa Cruz Biotechnology, sc21742), rabbit anti-bone sialoprotein
(IBSP) 1:100 (Biorbyt, orb1100, Cambridge, UK), rabbit anti-Runx2
1:50 (Santa Cruz Biotechnology, sc10758), goat anti-osteocalcin
(BGALP) 1:50 (Santa Cruz Biotechnology, sc18319). Secondary
antibodies were goat anti-mouse alexafluor 594 1:200 (Invitrogen,
A11005), goat anti-rabbit alexafluor 594 1:100 (Invitrogen, A11012),
donkey anti-goat FITC (Abcam, ab7121) and goat anti-rat Texas Red
1:200 (Sigma-Aldrich, SAB3700668).
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